Tripterygium glycoside tablet (TGT) has been used clinically to alleviate diabetic nephropathy (DN) for decades. However, the mechanism of its anti-DN has not been fully clarified. The aim of this study was to elucidate molecular mechanism of TGT in repairing renal function injury. The results of biochemical parameters and renal histopathology implied that TGT intervention could attenuate creatinine, albumin excretion rate and histological injury of kidney in DN mouse model. Moreover, UHPLC-QTOF-MS/MS-based untargeted metabolomic analysis indicated that 11 metabolites in kidney of mice with DN were restored after TGT treatment, and the most prominent metabolic alteration was triglyceride (TG) metabolism. Mechanistically, TGT effectively improved the function of impaired kidney by promoting TG catabolism via modulation of adipose triglyceride lipase in DN mice. Our findings identified the link between circulating metabolites and DN, suggesting that it might be a possibility to intervene in DN by targeting metabolism.High grade bladder cancer needs strict and close cystoscopic surveillance.Cancer patients are vulnerable to develop severe Covid-19 infection.Patients should be screened for Covid-19 before elective procedures.Covid-19 vaccination is a priority before elective procedures.Omadacycline is effective in patients with mild-to-moderate renal impairment.Omadacycline has similar safety as linezolid for patients with acute bacterial skin and skin structure infections, and similar safety as moxifloxacin for patients with community-acquired bacterial pneumonia.

Omadacycline provides a once-daily regimen independent of dose adjustments.Omadacycline is an option for those with or at risk of renal impairment or toxicity.In real-world studies, approximately 10% of patients hospitalized with acute bacterial skin and skin structure infections (ABSSSI) and 5% of patients hospitalized with pneumonia have been estimated to have renal impairment, such as chronic kidney disease. Renal impairment may change the clearance and impact the pharmacokinetics (PK) of antibiotics, resulting in the need for dosage adjustments. Inappropriate antibiotic dosages in patients with renal impairment can decrease efficacy if underdosed, as observed for ceftazidime-avibactam and ceftolozane-tazobactam, and increase the rates of adverse events and toxicity experienced by patients with renal disease if overdosed. Therefore, the health of the patient can be negatively affected and the overall healthcare costs increased.

visit for more articles at  Journal of Clinical & Experimental Nephrology

Kindly submit your article at https://www.imedpub.com/submissions/clinical-experimental-nephrology.html or nephrology@eclinicalsci.com 

Regards
Mishita
Jornal co-ordinator
Journal of Clinical & Experimental Nephrology